Miglitol combined with metformin improves glycaemic control in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 3, Issue 5, 2001, Pages 326-331

  Van Gaal, L ^a   Maislos, M ^b   Schernthaner, G ^c   Rybka, J ^d   Segal, P ^e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Hospital Rudolfstiftung   (Austria)

^d Bata Hospital   (Czech Republic)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hyperglycaemia; Metformin; Miglitol; Postprandial; Type 2 diabetes; glycosidase inhibitor

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PARAMETER; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY;

EID: 0035179630     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00141.x     Document Type: Article

References (23)

1. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
2. Effect of blood glucose control policy with metformin on complications in type 2 diabetes patients (UKPDS 34)
3. The effect of miglitol and acarbose after an oral glucose load: A novel hypoglycaemic mechanism?
4. Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials
5. Oral antidiabetic agents. The emergence of α-glucosidase inhibitors
6. Reduction of postprandial blood glucose by the α-glucosidase inhibitor miglitol (BAY m 1099) in type 2 diabetes
7. Acarbose: Its role in the treatment of diabetes mellitus
8. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated type 2 diabetic patients
9. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetes (NIDDM)
10. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with type 2 diabetes inadequately controlled by diet alone
11. Standards of medical care for patients with diabetes mellitus
12. Drug therapy of postprandial hyperglycaemia
13. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
14. Is fasting glucose sufficient to define diabetes?
15. Post-prandial glycaemic reduction by an α-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia
16. Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitus
17. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients
18. Efficacy of α-glucosidase inhibitors in NIDDM subjects
19. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone
20. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes
21. Acarbose safety review
22. Acarbose-induced severe hepatotoxicity